Abbott Laboratories (ABT) Accumulated Depreciation & Amortization (2009 - 2026)

Abbott Laboratories' Accumulated Depreciation & Amortization history runs 18 years deep, the most recent figure standing at $13.4 billion for Q1 2026.

• In Q1 2026, Accumulated Depreciation & Amortization rose 7.0% year-over-year to $13.4 billion; the TTM figure through Mar 2026 stood at $13.4 billion (up 7.0% YoY), while the FY2025 annual figure was $13.4 billion, up 10.96% from the prior year.
• Accumulated Depreciation & Amortization came in at $13.4 billion for Q1 2026 at Abbott Laboratories, roughly flat from $13.4 billion in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $13.4 billion in Q4 2025 to a low of $10.6 billion in Q1 2022.
• A 5-year average of $11.9 billion and a median of $11.8 billion in 2024 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization grew 2.57% in 2022 and gained 10.96% in 2025, its largest moves.
• Abbott Laboratories' Accumulated Depreciation & Amortization stood at $11.0 billion in 2022, then rose by 6.6% to $11.8 billion in 2023, then grew by 2.57% to $12.1 billion in 2024, then climbed by 10.96% to $13.4 billion in 2025, then dropped by 0.34% to $13.4 billion in 2026.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $13.4 billion, $13.4 billion, and $13.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison